N8-GP在既往接受过治疗的儿童A型血友病患者中的长期安全性与疗效:pathfinder5最终结果
pathfinder5是一项多国、开放标签、单臂、非随机、非对照试验,纳入68例年龄<12岁的重型A型血友病既往治疗男性患者,接受N8-GP 60 IU/kg每周两次,中位暴露约4.9年。未检出FVIII抑制剂(≥0.6 BU)或其他安全性问题,总体估算年化出血率为1.08(中位数0.81),近20%患者整个试验期间无出血。
要点
- 68例患儿接受N8-GP 60 IU/kg每周两次,中位暴露约4.9年,未检出FVIII抑制剂(≥0.6 BU)。
- 总体估算年化出血率为1.08(中位数0.81),近20%患者整个试验期间无出血。
- 暴露第4年56%患者无出血、86%无自发性出血,参与两阶段患者的所有基线靶关节在略超过2年内消退。
核心结论
- pathfinder5最终结果表明,中位4.9年的N8-GP长期治疗对既往治疗的重型A型血友病儿童患者有效且耐受性良好。
研究设计与样本
- pathfinder5(NCT01731600)为多国、开放标签、单臂、非随机、非对照试验,含主要阶段和扩展阶段。
- 纳入68例年龄<12岁的重型A型血友病既往治疗男性患者,主要阶段接受N8-GP 60 IU/kg每周两次共50个暴露日(约26周),扩展阶段维持相同方案至试验结束。
- 首例患者入组主要阶段时间为2013年2月20日,试验结束时间为2018年9月28日。
主要发现
- 68例患者接受N8-GP暴露,中位治疗时间约4.9年;进入扩展阶段的63例中62例完成试验。
- 未检出FVIII抑制剂(≥0.6 BU)或其他安全性问题。
- 总体估算年化出血率为1.08(中位数0.81),近20%患者整个试验期间无出血。
- 无年度出血的患者比例随时间增加,暴露第4年56%患者无出血、86%无自发性出血。
- 参与两阶段的患者所有基线靶关节在略超过2年内消退。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: N8-GP (turoctocog alfa pegol; Esperoct® , Novo Nordisk A/S, Bagsvaerd, Denmark) is a glycoPEGylated, extended half-life human recombinant factor VIII (FVIII). OBJECTIVE: Here, we report end-of-trial safety and efficacy results from the completed N8-GP pathfinder5 trial. METHODS: pathfinder5 (NCT01731600) was a multi-national, open-label, single-arm, non-randomized, non-controlled trial in previously treated male patients aged <12 years old with severe hemophilia A that comprised a main and an extension phase. During the main phase, patients received twice-weekly N8-GP 60 IU/kg for 50 exposure days (~26 weeks). During the extension phase, patients received the same regimen until the end of trial (first patient in main phase, 20 February 2013; trial end, 28 September 2018). RESULTS: Sixty-eight patients were exposed to N8-GP for a median time of ~4.9 years on regimen. Of the 63 patients who started in the extension phase, 62 completed the trial. No FVIII inhibitors (≥0.6 BU) or other safety concerns were detected. The overall estimated annualized bleeding rate was 1.08 (median 0.81), and nearly 20% of patients had no bleeds during the entire trial. The proportion of patients with no annual bleeds increased with time, with 56% of patients experiencing no bleeds and 86% experiencing no spontaneous bleeds during the fourth year of exposure. All baseline target joints of patients who participated in both phases of this trial were resolved in slightly over 2 years. CONCLUSION: Overall, data from the completed pathfinder5 trial show that long-term (median 4.9 years) N8-GP treatment was efficacious and well tolerated in previously treated pediatric patients with severe hemophilia A.
引用
- Šaulytė Trakymienė S, Economou M, Kenet G, et al. Long-term safety and efficacy of N8-GP in previously treated pediatric patients with hemophilia A: Final results from pathfinder5. J Thromb Haemost. 2020. PMID: 32940955. doi:10.1111/jth.15036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。